Jeanna Welborn, M.D. for UC Davis Health

Jeanna Welborn, M.D.

Medical Director, Adult Infusion Center, Hereditary Cancer Program

Professor (HSCP)

Medical Director, Adult Infusion Center

To see if Jeanna Welborn is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Reviews

Specialties

Benign and Malignant Hematology

Thrombosis

Leukemia

Locations and Contact

2279 45th Street
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Fax

916-703-5265

Clinic Referral Phone

916-703-5210

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Welborn believes in high quality, innovative, and compassionate care of his patients. She believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for her patients.

Clinical Interests

Dr. Welborn directs the Hereditary Cancer Program. Her interest is in benign and malignant hematology.

Research/Academic Interests

Dr. Welborn's research encompasses study of acute leukemias, oncogenes, cytogenetics and molecular epidemiology of cancer.

Division

Hematology and Oncology
Hereditary Cancer Program

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.A., Biology, Austin College, Sherman TX 1976

Medical School

M.D., University of Texas, Southwestern Medical School, Dallas TX 1982

Internship

Internal Medicine, Good Samaritan Medical Center, Portland OR 1982-1985

Residency

Internal Medicine, Good Samaritan Medical Center, Portland OR 1982-1985

Fellowship

Hematology/Oncology, UC Davis Medical Center, Sacramento CA 1985-1988

Fellowship

Clinical Cytogenetics, UC Davis Medical Center, Sacramento CA 1987-1988

UC Davis Health, Internal Medicine Clinician Award, 2017

Who's Who of American Small Colleges, 1976

For a comprehensive list of Dr. Welborn's publications, please click here (opens new window).

Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS. Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? CA Cancer J Clin. 2021 Jan;71(1):34-46. doi:10.3322/caac.21644. Epub 2020 Sep 30. PMID:32997807.

Toussi A, Mans N, Welborn J, Kiuru M. Germline mutations predisposing to melanoma. J Cutan Pathol. 2020 Jul;47(7):606-616. doi:10.1111/cup.13689. Epub 2020 May 11. PMID:32249949.

Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 Nov;94(11):E291-E294. doi:10.1002/ajh.25605. Epub 2019 Aug 20. PMID:31379016.

Li T, Stollenwerk N, Mans N, Welborn J, Lam K. Safety and Efficacy of Osimertinib in Treating a Metastatic Lung Cancer Patient with Concurrent Somatic EGFR L858R and Germline EGFR T790M Mutations. JCO Precision Oncology. 2018;2:1-7.

Su RJ, Jonas BA, Welborn J, Gregg JP, Chen M. Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia. Hum Pathol (N Y). 2016 Sep;5:6-9. doi:10.1016/j.ehpc.2015.10.001. PMID:27458550.

Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014 May;165(3):375-81. doi:10.1111/bjh.12755. Epub 2014 Mar 7. PMID:24606326.

Welborn J, Fenner S, Parks R. Features of polycythemia vera in the 8p12 myeloproliferative syndrome. Cancer Genet Cytogenet. 2010 May;199(1):53-5. doi:10.1016/j.cancergencyto.2010.01.013. PMID:20417870.

Welborn J, Fenner S, Parks R. Angioleiomyoma: a benign tumor with karyotypic aberrations. Cancer Genet Cytogenet. 2010 Jun;199(2):147-8. doi:10.1016/j.cancergencyto.2010.01.022. PMID:20471520.

Welborn J. Review: erythropoietin or darbepoetin for anemia in patients with cancer produces both benefits and harms with no increase in survival. ACP J Club. 2007 Jan-Feb;146(1):6. PMID:17203926.